Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐ho...

por Kiyosue, Arihiro, Seino, Yutaka, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Kaku, Kohei
Publicado 2017

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical tria...

por Kaneko, Shizuka, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Kaku, Kohei, Seino, Yutaka
Publicado 2018

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide...

por Seino, Yutaka, Miyoshi, Hideaki, Bosch Traberg, Heidrun, Divyalasya, T V S, Nishijima, Keiji, Terauchi, Yasuo
Publicado 2022

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐gro...

por Kaku, Kohei, Kiyosue, Arihiro, Ono, Yuri, Shiraiwa, Toshihiko, Kaneko, Shizuka, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Seino, Yutaka
Publicado 2015

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

por Seino, Yutaka, Kaneko, Shizuka, Fukuda, Shuichi, Osonoi, Takeshi, Shiraiwa, Toshihiko, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Kaku, Kohei
Publicado 2016

Liraglutide and Glycaemic Outcomes in the LEADER Trial

por Zinman, Bernard, Nauck, Michael A., Bosch-Traberg, Heidrun, Frimer-Larsen, Helle, Ørsted, David D., Buse, John B.
Publicado 2018

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN...

por Rossing, Peter, Bain, Stephen C., Bosch-Traberg, Heidrun, Sokareva, Ekaterina, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G.
Publicado 2023

Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial

por Nauck, Michael A., Buse, John B., Mann, Johannes F. E., Pocock, Stuart, Bosch‐Traberg, Heidrun, Frimer‐Larsen, Helle, Ye, Qing, Gray, Alastair
Publicado 2018

Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population

por Funch, Donnie, Mortimer, Kathleen, Ziyadeh, Najat J., Seeger, John D., Li, Ling, Norman, Heather, Major‐Pedersen, Atheline, Bosch‐Traberg, Heidrun, Gydesen, Helge, Dore, David D.
Publicado 2019

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population

por Funch, Donnie, Mortimer, Kathleen, Ziyadeh, Najat J, D Seeger, John, Zhou, Li, Ng, Eva, Ross, Douglas, Major-Pedersen, Atheline, Bosch-Traberg, Heidrun, Gydesen, Helge, Dore, David D
Publicado 2021

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

por Rossing, Peter, Baeres, Florian M M, Bakris, George, Bosch-Traberg, Heidrun, Gislum, Mette, Gough, Stephen C L, Idorn, Thomas, Lawson, Jack, Mahaffey, Kenneth W, Mann, Johannes F E, Mersebach, Henriette, Perkovic, Vlado, Tuttle, Katherine, Pratley, Richard
Publicado 2023

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

por Tack, Cees J., Jacob, Stephan, Desouza, Cyrus, Bain, Stephen C., Buse, John B., Nauck, Michael A., Petrie, John R., Poulter, Neil R., Pratley, Richard E., Stegmann, Helen Vanya B. K., Bosch‐Traberg, Heidrun, Startseva, Elena, Zinman, Bernard
Publicado 2019